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Methods
A Phase I study was conducted with i plasmid DNA
vaccine, containing the CryJ2 allergen from Japanese
Red Cedar inserted into the Lysosomal Associated
Membrane nucleic acid sequence. Previouslyy sensitized
Japanesei, were consented in English/Japanese, received
four doses and assessed over 132 days for the safety of
this vaccine. Group 1 contained non-sensitive and
Groups 2 & 3 sensitive subjects as defined by +/- skin
test to JRC, Mountain cedar and CryJ2 allergens. All
subjects received 4 doses at 14 day intervals.
Safety data through 132 days after the 1st vaccination
showed 85% of the adverse events (AE’s) were mild, mainly
injection site erythema, swelling and pain, the majority
occurring in Group 3.t All AEs were of a transient nature,
requiring no medical attention. CryJ2-LAMP-Vax did not
induce IgE CryJ2 specific titer changes, nor CryJ2 specific
IgG titers. Prior to each vaccination and at 72 and 132
days, subjects tested negative for anti-LAMP antibodies.
These clinical and biomarker data suggested that the plas-
mid vaccine was safe.
Results
At 132 days, the skin prick tests indicated that the CryJ2-
LAMP-Vax converted 10 of 12 subjects’ JRC positive skin
test reactions to negative, with a similar conversion pat-
tern in 6/11 Mountain cedar skin test positive; Mountain
cedar Jun a 2 allergen shares a 91% homology with CryJ2.
These subjects presumptively were sensitive to the Jun a2
allergen, 91% homologous to CryJ2.
Conclusions
The most striking observation at Day 132 was the conver-
sion of positive skin test reactions to unrelated allergens-
Southern Grass mix, Western Ragweed mix, Southern
California Tree Mix and Dust Mite Mix, to negative at
day 132. In Groups 2 & 3, the conversion was 10/17 sub-
jects. The vaccinated non-CryJ2 sensitive subjects exhib-
ited no skin test conversions. These skin test conversions
from positive to negative at day 132 for allergens unre-
lated to CryJ2, possibly represents a general T cell
immune response due to the DNA vaccine.
The Phase I clinical data and laboratory results support
the conclusion that vaccination with CryJ2-LAMP-Vax is
safe and changes the immune status. The majority of AE’s
were mild skin injection reactions, primarily in the high
dose /Group 3. There were no anaphylactic reactions from
the vaccination. The lack of any significant IgE anti-CryJ2
responses in both vaccinated non-atopic sensitive and ato-
pic sensitive subjects indicated a conversion of the
immune status to CryJ2 from a Th2 into a Th1 response.
The skin test conversions of 21 subjects JRC/MC/CryJ2
skin tests to negative at day 132, suggests that the DNA-
LAMP vaccine modulated the immune system. Further, it
is suggested that the positive to negative skin test conver-
sions for allergens unrelated to CryJ2 specificity, possibly
represents a general bystander T cell regulatory response.
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